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Abstract
Aims: Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as being
inferior to that in some Western countries. As there is a range of survival across the UK we hypothesised that in major regional centres, outcomes are equivalent
to the best internationally.
Materials and methods: Data from patients treated in multicentre international and UK-based trials were obtained from three regional cancer centres in the UK;
Manchester, University College London and Leeds (MUL). The median progression-free survival (PFS) and overall survival were calculated for each trial and
compared with the published trial data. Normalised median survival values and the respective 95% conﬁdence intervals (ratio of pooled MUL data to trial
median survival) were calculated to allow inter-trial survival comparisons. This strategy then allowed a comparison of median survival across the UK, in three
regional UK centres and in international centres.
Results: The analysis showed that the trial-reported PFS was the same in the UK, in the MUL centres and in international centres for each of the trials included in
the study. Overall survival was, however, 45% better in major regional centre-treated patients (95% conﬁdence interval 9e73%) than the median overall survival
reported in UK trials, whereas the median overall survival in MUL centres equated with that achieved in international centres.
Conclusion: The data suggest that international survival statistics are achieved in UK regional cancer centres.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Ovarian carcinoma is responsible for over 4000 deaths
each year in the UK; more than all other gynaecological
cancers combined. The standard treatment in the ﬁrst-line
setting is debulking surgery followed by cytotoxicAuthor for correspondence: G.C. Jayson, The Christie NHS Foundation
Trust and Institute of Cancer Sciences, University of Manchester,
Withington, Manchester M20 4BX, UK. Tel: þ44-161-446-7029.
E-mail address: Gordon.Jayson@christie.nhs.uk (G.C. Jayson).
http://dx.doi.org/10.1016/j.clon.2016.06.011
0936-6555/ 2016 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).chemotherapy with carboplatin and paclitaxel. Strategies to
improve outcomes include the use of preoperative chemo-
therapy [1,2], dose-dense chemotherapy [3,4] or the addi-
tion of anti-angiogenic agents to standard doublet therapy
[5e8].
In keeping with these advances, survival outcomes for
ovarian cancer have improved worldwide, including in the
UK. However, survival in the UK has been consistently re-
ported to be worse than that in some other European
countries, North America and Australia [9,10]. Within the
UK there is evidence of variation in outcomes betweend. This is an open access article under the CC BY-NC-ND license (http://
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related to socio-economic status [13] than to other prog-
nostic factors at presentation. One critical issue is the
quality of care, particularly after initial relapse, and to
address this we collected ovarian cancer survival data from
three UK cancer centres, which participated in ﬁve recent
randomised trials in ovarian carcinoma. Our aim was to
compare the progression-free survival (PFS) and overall
survival statistics of women treated in regional cancer
centres in the UK with those of women treated across the
UK and internationally. We aimed to test the hypothesis
that UK, major regional cancer centre-associated survival
was superior to other UK centres.Fig 1. Overall survival in specialist cancer centres, international
centres and the UK average survival. The data show the relative
overall survival for patients treated in UK-centric trials, deﬁned as
unity and labelled as Mean UK OS. The Manchester, UCL and Leeds
(MUL) centre overall survival is labelled as Centre OS, showing a 45%
increase in overall survival in centre-treated patients, when
compared with Mean UK OS. This is compared with the overall sur-
vival achieved by the MUL group in international clinical trials (the
International OS bar). The International OS bar reﬂects the relative
survival of MUL patients to the median overall survival of the inter-
national trial set compared with the UK OS, which is deﬁned as 1. The
MUL centre overall survival statistic is presented as  95% conﬁdence
intervals.Materials and Methods
Selection of Clinical Trials for Evaluation
Trials were selected if recently completed, overall sur-
vival statistics were available and the MUL centres had
recruited sufﬁcient numbers of patients to allow meaning-
ful analysis. Five clinical trials met these criteria. The design
and statistical plan for each trial have been described in the
primary publications. Three trials involved patients
receiving ﬁrst-line treatment for ovarian cancer: CHORUS
[2], GOG-0182-ICON5 [14] and ICON7 [6,7]. Two were in
recurrent disease: ICON6 [8] and SaPPrOC [15], which
recruited patients with platinum-sensitive and platinum-
resistant disease, respectively.
The numbers of UK women recruited to each of the trials
is presented as the numerator and the total number in the
trial as the denominator: ICON5 363/4312 (8.4%); ICON7
375/1528 (24.5%); ICON6 379/486 (78%); SAPPROC 107/107
(100%); CHORUS 539/552 (97.6%). Trials were categorised as
having been predominantly UK based (ICON6, CHORUS and
SAPPROC) or international (ICON5 and ICON7). Thus, of the
international group of trials, the UK contribution was 12.6%
and in the UK-centric group of trials the contribution was
89.5% of patients.
Comparison of Specialist Centres and Overall Study
Populations
Data were extracted from clinical trial databases and
supplemented with clinical records for patients treated in
threemajor regional cancer centres in the UKwith expertise
in the management of women with gynaecological cancers
and in clinical trials (The Christie NHS Foundation Trust,
Manchester; University College London Hospitals NHS
Foundation Trust, London; and the St James’s Institute of
Oncology, Leeds: MUL).
Pre-treatment characteristics including FIGO stage, sur-
gical outcomes and post-progression therapy were
compared with those of the relevant overall trial pop-
ulations. No distinction was made between the arms to
which the patients were randomised and thus survival data
across trial arms were summated for comparative purposes.
KaplaneMeier analysis, calculated from the date of studyentry to the last available follow-up censored in September
2014, was used to calculate the median PFS and overall
survival for MUL patients. MULmedian survival values were
then compared with those in the overall trial populations,
taken from published data.
The median PFS and overall survival data were sum-
marised further by calculating the ratio between the MUL
median PFS or overall survival value and the trial median
PFS or overall survival value for each study, where the trial
median PFS or overall survival for the UK-centric studies
was deﬁned as 1. In the ﬁrst part of the analysis we
compared MUL survival with the median survival for UK-
centred studies. We then compared the MUL survival sta-
tistics with the median survival in international trials,
enabling a comparison between the three groups. The 95%
conﬁdence interval ratios for the MUL subset median values
were similarly calculated.
When summating ratios from trials together to allow a
comparison between MUL, UK and international data, the
numbers of MUL patients recruited to each trial were used
to weight the calculated overall survival ratio so that trials
where MUL centres recruited more patients had a greater
effect on the overall calculated survival ratio. Thus, the
summated mean overall survival ratio (Figure 1) was
calculated as: the sum of the products of the MUL survival
ratio for each trial and the number of patients recruited
from MUL centres to that trial, divided by the total number
of MUL patients.
The effect of post-progression (off-trial) treatment was
assessed using a post-progression survival ratio, calculated
from the difference between median PFS and overall sur-
vival between MUL and overall trial populations.
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median overall survival was calculated and the data ana-
lysed according to two deﬁned groups: UK-centric trials
(ICON6, CHORUS and SAPPROC) or international trials
(ICON5 and ICON7). This strategy allowed us to compare the
effect of centre-based treatment with the overall results for
the UK and with international trial statistics.Results
The primary results of the trials have been published. In
brief, CHORUS [2], GOG-0182-ICON5 [14] and SaPPrOC [15]
showed no signiﬁcant difference in PFS between control
and investigational regimens, whereas ICON6 [8] and ICON7
[6,7] reported signiﬁcantly improved PFS with the addition
of concurrent and maintenance anti-angiogenic therapy to
chemotherapy.
The MUL subset comprised 8% of the overall study
populations within the CHORUS, GOG-0182-ICON5 and
ICON7 trials and a larger proportion of patients in ICON6
(27%) and SaPPrOC (29%) (Table 1). Within theMUL data set,
the proportion of patients randomised to the investiga-
tional arm resembled that in the overall study population
(Table 1) and the patient characteristics with respect to
FIGO stage and surgical outcome were also similar to the
overall patient population for each trial (Table 1). The only
exceptionwas that in ICON7 fewer MUL patients had<1 cm
disease after debulking surgery.
Survival Outcome Comparisons between MUL and Overall
Trial Populations
The survival data are summarised in Table 2, which also
shows that the median duration of follow-up for MUL and
ITT populations were comparable. The median PFS in the
MUL subset was similar to that of the speciﬁc trial pop-
ulations for both UK-centric and international trials. The
95% conﬁdence interval for the MUL subset largely
encompassed the median value for the overall trialTable 1
Summary of patient populations; Manchester, UCL and Leeds (MUL) co
CHORUS [2] SaPPrOC [15]
Recruitment period 2004e2010 2011e2012
MUL ITT MUL
No. patients 45 550 31
Percentage in investigational arm 49 50 double blinde
FIGO stage (%)
III 76 75
IV 24 25
Residual disease (%)
1 cm 47 56
>1 cm 27 44
ITT, Intention to Treat.
ICON6 and SaPPrOC are trials for recurrent disease and therefore the init
the primary publications.populations. In CHORUS, however, the median PFS and
corresponding 95% conﬁdence interval were greater than
the median value for the overall study population; 15.4
months (95% conﬁdence interval 11.5e17.2, P < 0.05) in the
MUL group and 11.3 months in the overall trial. In ICON7 the
median PFS in the MUL subset was shorter (16.8 months)
than the overall trial population (18.7 months) but the 95%
conﬁdence interval for the MUL subset included this value,
indicating that the difference was not statistically
signiﬁcant.
In UK-based trials, the median overall survival ratios in
the MUL subset were for the SaPPrOC trial 1.59 (95% con-
ﬁdence interval 0.65e2.01), for CHORUS 1.57 (95% conﬁ-
dence interval 1.11e2.10) and for ICON6 1.37 (95%
conﬁdence interval 1.19e1.65). For international studies, the
MUL subset median overall survival was equivalent to that
of ICON5 but in ICON7 the median MUL overall survival
ratio was slightly lower than in the overall trial population,
but this was not statistically signiﬁcant (0.89, 95% conﬁ-
dence interval 0.66e1.26; not signiﬁcant). Table 2 summa-
rises PFS and overall survival outcomes in the overall trial
populations and in the MUL subset of patients. The median
durations of follow-up for MUL and ITT populations were
comparable (Table 2).
The overall survival result from the MUL ICON7 patients
led us to explore the data further. In ICON7, a pre-speciﬁed
subgroup, consisting of high-risk patients [6], seemed to
beneﬁt from bevacizumab and cytotoxic chemotherapy. The
overall population, however, which included patients with
FIGO stage IC‒IV disease, derived only modestly improved
PFS. We therefore also examined the overall survival of
patients in this high-risk group. Of the MUL ICON7 patients,
28 of 62 patients (45%) were deﬁned as high risk compared
with only 30% in the ITT population. Thus, the MUL subset
seemed to represent a relatively poorer prognostic group.
Nevertheless, this high-risk subgroup achieved the same
median overall survival in the MUL centres as that seen in
the high-risk subgroup within the overall trial population
(overall survival ratio 1.01, 95% conﬁdence interval
0.83e1.4; not signiﬁcant).mpared with trial populations as a whole
ICON6 [8] GOG-0182-
ICON5 [14]
ICON7 [6,7]
2007e2011 2001e2004 2006e2009
ITT MUL ITT MUL ITT MUL ITT
107 124 456 47 4312 62 1528
d 66 69 74 79 80 47 50
79 84e87 76 68
21 13e16 11 13
45 69 52 73
51 31 42 25
ial FIGO stage and residual disease statistics were not available from
Table 2
Median survival statistics in Manchester, UCL and Leeds (MUL) and overall trial data
CHORUS [2] SaPPrOC [15] ICON6 [8] ICON5 [14] ICON7 [6,7] ICON7 high-risk
subgroup
Median duration of follow-up, years
MUL subset 3 1.1 2.5 4.5 4 3
ITT population 3 NR NR 3.7 4 NR
Median PFS, months (95% conﬁdence interval)
MUL subset 15.4 (11.5e17.2) 5.0 (3.7e7.6) 10.1 (9.5e11.0) 20.6 (15.7e27.7) 16.8 (13.8e18.9) 13.0 (1.0e55.0)
ITT population 11 4.7 10 15.9 18.7 13.2
Median overall survival, months (95% conﬁdence interval)
MUL subset 37.7 (26.7e50.3) 19.1 (7.8e24.2) 31.4 (27.3e37.9) 53.9 (41e113) 51.6 (38e73) 35.5 (29.2e49.1)
ITT population 24 12 23 44 58 35
Survival ratios MUL compared with ITT trial populations
PFS 1.4 1.08 1.0 1.3 0.90
Overall survival 1.57 1.59 1.37 1.23 0.89 1.01
Post-progression
survival ratio
1.7 1.91 1.78 1.18 0.87
MUL, Manchester, UCL, Leeds; ITT, Intention to Treat; PFS, progression-free survival.
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Manchester, UCL and Leeds (MUL) and Trial ITT Data
We normalised the MUL survival statistics for the two
groups of trials against the median overall survival achieved
in UK-based trials. In the UK-based trials, the analyses
showed that the overall survival ratios were relatively
higher in the MUL subset of patients for all three trials. The
combined weighted mean, which takes into account the
numbers of patients recruited to a particular trial, for all
three trials was 1.45 (95% conﬁdence interval 1.09e1.80),
implying that MUL centres achieved statistically signiﬁ-
cantly better overall survival than UK centres overall, while
matching the survival statistics achieved in international
centres (Figure 1).
For the international trials, the calculated overall survival
ratio was 1.23 (95% conﬁdence interval 0.93e2.57) in ICON5
and 0.89 (95% conﬁdence interval 0.66e1.26) in the total ITT
ICON7 populations, reﬂecting the case mix of patients
recruited to ICON7 in the MUL centres. The weighted mean
overall survival ratio for both of these trials was 1.04 and the
95% conﬁdence interval indicated no signiﬁcant difference
in outcome between the MUL centres and the international
participating centres.
Optimum Debulking and Post-progression Treatment at MUL
Centres
Two potential explanations for superior outcomes at
MUL centres include superior cytoreductive surgery at MUL
centres and greater use of post-progression therapy and, in
particular, dose-dense cytotoxic regimens at these centres.
Looking at the MUL CHORUS patients who underwent pri-
mary surgery, 21 of 33 patients (64%) had optimum
debulking surgery, whereas the overall trial statistic
described 41% of such patients achieving this degree of
cytoreductive surgery. With respect to post-progression
statistics, the ICON6 data set was the largest, including
data from 125 MUL-treated patients. This data set showedthat the MUL centres provided a median of two post-
progression regimens, with a range of up to six. Patients
received a median of one dose-dense regimen, where
cytotoxic therapy is given on a weekly basis, with a range of
up to three such regimens.Discussion
Our analyses suggest that survival outcomes in regional
referral centres in the UK treating high numbers of women
with ovarian cancer are similar to those observed interna-
tionally and are signiﬁcantly better than the average sur-
vival in the UK, resulting in a 45% improvement in overall
survival when compared with the national average.
One hypothesis to explain the improved survival might
be that there is an element of selection bias, which favoured
treatment in the MUL centres. However, this is unlikely to
be the case as Table 1 shows that the demographic char-
acteristics of MUL patients closely resemble those of the
overall trial populations. Furthermore, if one accepts that
these demographic characteristics are similar, then
protocol-deﬁned treatments should result in the same PFS,
whether patients are treated in a regional cancer centre or
not; the data that we present here support this hypothesis.
Thus, the equality of patients’ demographic characteristics
and PFS suggest that case selection bias does not explain the
improved outcome in large regional cancer centres. Rather,
the data suggest that the differences in survival probably
arise because of care provided after the patient leaves the
clinical trial protocol-deﬁned regimen, which is usually at
the point of developing progressive disease. In other words,
MUL centres may provide more effective post-relapse
therapy.
The explanation for the improved survival cannot be
precisely and reliably determined from this analysis, as
post-progression therapy details were not available from
the primary publications. However, it is noteworthy that
in the Oceans [16,17] trial, a recent international
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ovarian cancer, a third of patients received at least seven
lines of therapy. The median overall survival for both arms
of the Oceans trial was 33 months, which equates with the
median overall survival of MUL patients participating in
ICON6.
Our analysis is retrospective and is therefore subject to
confounding factors. For example, the median PFS and
overall survival statistics in the MUL subsets were calcu-
lated from the pooled groups of patients, irrespective of the
arms to which the patients were randomly assigned. For
studies that showed no signiﬁcant difference between
treatment arms this is not a concern, but for ICON6 and
ICON7, where the investigational arms were superior, this
approach might incur unforeseen bias. On the other hand,
we chose this approach because the randomisation of
demographically balanced groups of patients should have
adjusted for this potential issue and because post-
progression treatment, reﬂecting overall quality of care,
would apply to the entire trial cohort. The proportions of
women included in each treatment armwere in fact similar
between the MUL and the ITT populations.
The trials that were included in this study were selected
on the basis that the overall survival statistics of partici-
pating patients were available. As some trials started 10
years ago it is possible that the overall management of the
disease in the UK is now more uniform, e.g. higher rates of
complete cytoreduction, which might reduce the magni-
tude of differences identiﬁed here. However, the Calman-
Hine report was published in 1995 and therefore when
these trials were initiated the effect of centralisation should
already have been well established.
Another confounding factor is that MUL outcomes were
compared with those of the entire trial population without
excluding MUL participants. It is possible therefore that
with respect to the UK-centred trials, the superior outcomes
in MUL treated women may have been diluted. Neverthe-
less, it is important to note that our data do not suggest that
theMUL centres offer superior treatment to that available in
other large UK regional cancer centres. The MUL centres
were selected because they were considered representative
of major research-active UK centres. The high level of
recruitment activity to key randomised trials at these cen-
tres provided us with enough patients and data to allow a
meaningful analysis to be carried out. It is probable that
other large regional centres in the UK would have similar
survival statistics.
The use of the median to estimate the magnitude of
treatment effect could be questioned. In both ICON6 and
ICON7, non-proportional hazards were observed and
therefore the restricted mean was considered a more
appropriate estimate of treatment effect. To enable a com-
parison between all the studies we therefore used the me-
dian survival statistic, which seemed reasonable given the
similarity in median follow-up interval between the MUL
and overall trial populations.
The results of this study suggest that the superior overall
survival achieved in large regional cancer centres in the UK,
compared with centres overall, resulted from longer post-progression survival. We believe that the most likely
explanation lies in a more determined approach to control
disease in the platinum-sensitive and platinum-resistant
disease settings. Although some women in the UK may be
less prepared to undergo repeated lines of chemotherapy,
than for example in the USA, this would not account for
within UK differences. Whereas ‘standard of care’ chemo-
therapy can be readily administered in all designated cancer
centres in the UK, post-progression treatment can be more
toxic and less well tolerated, requiring a stronger clinical
infrastructure, which is available in large centres. Although
quality of life issues remain to be determined, this study
provides a basis for re-thinking the optimum framework for
managing recurrent ovarian cancer in the UK, which might
require further centralisation of care to highly specialised
multidisciplinary teams that could offer access to, for
example, dose-dense therapy, secondary cytoreductive
surgery and/or the broad portfolio of new agents available
in phase IeIII clinical trials at such centres.Conclusions
It is reassuring that MUL centres achieve international
outcome standards. However, the overall survival statistics
across the UK remain inferior to many other Western na-
tions [18] and further work should identify the underlying
explanations for the differences.
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